Answer
Rifampicin, a strong CYP3A inducer, at 600 mg once daily decreased fruquintinib exposure (AUC) by 65% and peak concentration (Cmax) by 12%, so concomitant use should be avoided.
Sources for this answer
- FRUZAQLA 1 mg hard capsulesTakeda UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 3Document updated
Sources checked